Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times

Xu,Yan-Yan; Jiang,Na; Liu,Tong-Shen; Qu,Hui-Qing; Wang,Tian

doi:10.3892/mmr.2012.1033

November 2012 Volume 6 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2012 Volume 6 Issue 5

Full Size Image

Article

Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times

Authors:
- Yan-Yan Xu
- Na Jiang
- Tong-Shen Liu
- Hui-Qing Qu
- Tian Wang
View Affiliations / Copyright

Affiliations: Department of Cell Biology, Binzhou Medical University, Yantai, Shandong, P.R. China, Department of Pharmacy, Dalian Sixth People's Hospital, Dalian, Liaoning, P.R. China, Department of Histology and Embryology, Binzhou Medical University, Yantai, Shandong, P.R. China, Department of Transfusion, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, P.R. China , Department of Pharmacology, School of Pharmacy, Yantai University, Yantai, Shandong, P.R. China
Pages: 1075-1080
|
Published online on: August 13, 2012

https://doi.org/10.3892/mmr.2012.1033
Expand metrics +

Abstract

Cisplatin (cis-diamminedichloroplatinum, CDDP) is one of the most potent anticancer drugs. However, the therapeutic value of CDDP is greatly compromised by its dose-limiting nephrotoxicity. This study was performed to investigate whether reduced glutathione (GSH) was able to reduce the kidney injury induced by CDDP and whether it affected the anticancer activity of CDDP in vivo and in vitro. In in vivo experiments, mice were divided into five groups: control, CDDP only and three GSH treatment groups. Blood samples were collected 72 h after CDDP administration to determine the levels of blood urea nitrogen (BUN) and plasma creatinine (Cr). In addition, we examined antioxidative parameters, malondialdehyde (MDA) levels and histopathological changes in the kidney. In order to investigate whether GSH affected the anticancer activity of CDDP, we performed a sulforhodamine B (SRB) assay to determine the antiproliferative effect in three tumor cell lines of treatment with CDDP alone or combined with GSH and examined the cell morphology. The results revealed that GSH decreased the BUN and Cr levels in plasma, ameliorated the pathological changes induced by CDDP and enhanced the endogenous antioxidant capacities in all three GSH groups. Furthermore, GSH significantly inhibited the growth of the three tumor cell lines when combined with CDDP and did not affect the inhibitory effect of CDDP on the carcinoma cell proliferation. In addition, we found no differences among the three GSH groups. These findings suggest that GSH is able to attenuate the nephrotoxicity induced by CDDP, not only when administered prior to CDDP, but also when administered at the same time as or subsequent to CDDP administration, without affecting the anticancer activity of CDDP. Thus, the administration of GSH is a promising approach for attenuating the nephrotoxicity caused by CDDP.

View Figures

View References

1	Schrier RW: Cancer therapy and renal injury. J Clin Invest. 110:743–745. 2002. View Article : Google Scholar : PubMed/NCBI
2	Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM and Mingeot-Leclercq MP: Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 13:11–32. 2008. View Article : Google Scholar : PubMed/NCBI
3	Madias NE and Harrington JT: Platinum nephrotoxicity. Am J Med. 65:307–314. 1978. View Article : Google Scholar : PubMed/NCBI
4	Taguchi T, Nazneen A, Abid MR and Razzaque MS: Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol. 148:107–121. 2005. View Article : Google Scholar : PubMed/NCBI
5	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
6	Daugaard G: Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull. 37:1–12. 1990.PubMed/NCBI
7	Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F and Tofanetti O: Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact. 70:89–101. 1989. View Article : Google Scholar
8	Ajith TA, Usha S and Nivitha V: Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta. 375:82–86. 2007. View Article : Google Scholar : PubMed/NCBI
9	Jiang N, Lu L, Wang T, Zhang L, Xin W and Fu F: Reduced glutathione attenuates liver injury induced by methyl parathion in rats. Toxicol Mech Methods. 20:69–74. 2010. View Article : Google Scholar : PubMed/NCBI
10	Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
11	Jariyawat S, Kigpituck P, Suksen K, Chuncharunee A, Chaovanalikit A and Piyachaturawat P: Protection against cisplatin-induced nephrotoxicity in mice by Curcuma comosa Roxb. ethanol extract. J Nat Med. 63:430–436. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kuhad A, Pilkhwal S, Sharma S, Tirkey N and Chopra K: Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem. 55:10150–10155. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kawai Y, Taniuchi S, Okahara S, Nakamura M and Gemba M: Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull. 28:1385–1388. 2005. View Article : Google Scholar : PubMed/NCBI
14	Dobyan DC, Levi J, Jacobs C, Kosek J and Weiner MW: Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 213:551–556. 1980.PubMed/NCBI
15	Ali BH and Al Moundhri MS: Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 44:1173–1183. 2006. View Article : Google Scholar : PubMed/NCBI
16	Xu Y, Jiang N and Yu H: Effect of glutathione combined with cisplatin and oxaliplatin on the proliferation and apoptosis of lung carcinoma cell line. Toxicol Mech Methods. 20:487–492. 2010. View Article : Google Scholar : PubMed/NCBI
17	Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS and Kim YK: Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med. 142:178–186. 2003. View Article : Google Scholar : PubMed/NCBI
18	Jordan P and Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 57:1229–1235. 2000. View Article : Google Scholar : PubMed/NCBI
19	Vermeulen NP and Baldew GS: The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol. 44:1193–1199. 1992. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles